The All India Institute of Medical Sciences, New Delhi, in partnership with Radiosurgery Global India, begins clinical use of the Hyperfine Swoop\u00ae portable MRI system<\/i><\/p>\n
NEW DELHI–(BUSINESS WIRE<\/a>)–Hyperfine, Inc.<\/a> (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain\u2014the Swoop\u00ae system\u2014and the All India Institute of Medical Sciences (AIIMS), New Delhi, India’s foremost medical institution, today announced that AIIMS New Delhi has initiated clinical use of the Swoop\u00ae portable MRI system. AIIMS New Delhi is the first hospital in India to deploy bedside MRI for routine clinical use, marking an important milestone for neurological care across the country.<\/p>\n \nIn a collaboration between Radiosurgery Global Ltd. (the exclusive Swoop\u00ae system distributor in India) and AIIMS New Delhi’s Centre for Neurological Conditions, the Swoop\u00ae system is now performing bedside brain imaging for routine clinical care under the leadership of Dr. Shailesh Gaikwad, Head of the Department of Neuroimaging and Interventional Neuroradiology and Chief of the Neuroscience Centre at AIIMS New Delhi.<\/p>\n \n\u201cBedside brain imaging transforms how we care for our most critically ill patients. At AIIMS, we manage thousands of stroke and ICU patients annually, where rapid neuroimaging is essential\u2014yet transport to conventional MRI is often unsafe or impossible. The Swoop\u00ae system eliminates that barrier. Now our clinicians can obtain diagnostic images at the point of care, enabling faster decision-making in neurology, trauma, and critical care. For a medical institution like ours that serves as a referral center across India, this deployment signals what’s possible when technology and clinical need align to advance neurological care,\u201d said Dr. Shailesh Gaikwad, Head, Department of Neuroimaging and Interventional Neuroradiology and Chief of Neuroscience Centre AIIMS New Delhi.<\/p>\n Why This Matters for India<\/b><\/p>\n \nIndia is home to over a billion people across diverse geographies, including urban megacities, remote districts, rural communities, and everything in between. Across this landscape, timely access to neuroimaging remains a significant challenge. When patients suffer a stroke, sustain a brain injury, or present with a neurological emergency, the imaging required for diagnosis and treatment is often delayed or unavailable.<\/p>\n \nConventional high-field MRI systems require dedicated shielded rooms, specialized infrastructure, and patient transport. For critically ill patients in ICUs, trauma bays, neurosurgery wards, neonatal units, and emergency departments, transport is often not feasible. These limitations can delay diagnosis and treatment and impact outcomes.<\/p>\n \nThe Swoop\u00ae system addresses these barriers by bringing MRI directly to the point of care. It requires no dedicated room, specialized power, or patient transfer. Clinicians can roll the system to the patient\u2019s bedside in the ICU, trauma center, stroke unit, or neonatal ward and obtain brain images when and where they are needed most.<\/p>\n The Breadth of Clinical Impact<\/b><\/p>\n \nThe Swoop\u00ae system supports a wide range of unmet clinical needs across India\u2019s healthcare ecosystem:<\/p>\n \nDeployment at AIIMS New Delhi marks the beginning of broader adoption across India, bringing point-of-care brain imaging to clinical environments where it can have the greatest impact.<\/p>\n \n\u201cBringing the Swoop\u00ae system to AIIMS New Delhi is an important milestone following regulatory approval last December. India has a significant unmet need for accessible brain imaging. Deployment at the country\u2019s leading institution signals the start of bringing point-of-care brain MRI to sites of care and institutions across India, where it can serve clinicians and their patients across neurological conditions,\u201d said Maria Sainz, President and CEO of Hyperfine.<\/p>\n \n\u201cRadiosurgery Global exists to democratize access to transformative technologies. We’re proud that the Swoop\u00ae system’s first clinical deployment in India is at AIIMS New Delhi\u2014an institution that shares our commitment to advancing patient care across this vast, underserved landscape. This isn’t just a regulatory or commercial milestone\u2014it’s the beginning of changing outcomes for critically ill patients in ICUs, trauma units, and stroke centers nationwide,\u201d said Kapil Kalra, Managing Director, Radiosurgery Global Ltd.<\/p>\n A Platform for Clinical Research and Discovery<\/b><\/p>\n \nThe Swoop\u00ae system deployment at AIIMS New Delhi also establishes a foundation for clinical research. As a leading center for neuroscience research and clinical innovation, AIIMS New Delhi is uniquely positioned to generate real-world evidence to guide the adoption and utilization of portable MRI across India. The AIIMS New Delhi team plans to document outcomes, contribute to peer-reviewed publications, and advance India\u2019s role in the growing global evidence base for point-of-care brain imaging.<\/p>\n \nFor more information about the Swoop\u00ae system, please visit HyperfineMRI.com<\/a>.<\/p>\n About the Swoop\u00ae Portable MRI Systems About Hyperfine, Inc. About AIIMS New Delhi About Radiosurgery Global Ltd. \nHyperfine, the Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine.<\/p>\n Forward-Looking Statements View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260429706357\/en\/<\/a><\/span><\/p>\n Media Investor KEYWORDS:<\/b> India Asia Pacific<\/p>\n INDUSTRY KEYWORDS:<\/b> Technology Biotechnology FDA Health Neurology Pharmaceutical Artificial Intelligence Other Technology Research General Health Hospitals Health Technology Science Clinical Trials<\/p>\n\n
\n
\n
\n
\n
\n
<\/b>The Swoop\u00ae Portable MR Imaging\u00ae Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.<\/p>\n
\n
<\/b>Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop\u00ae system\u2014the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop\u00ae system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit HyperfineMRI.com<\/a>.<\/p>\n
\n
<\/b>The All India Institute of Medical Sciences (AIIMS), New Delhi, established in 1956, is India’s premier autonomous public medical university and national referral center for tertiary healthcare, medical education, and biomedical research. AIIMS New Delhi consistently ranks as the number one hospital in India and trains thousands of specialists who go on to shape clinical practice nationwide. The Centre for Neurological Conditions (CNC) at AIIMS New Delhi is one of India’s foremost centers for neurological care, research, and innovation.<\/p>\n
\n
<\/b>Radiosurgery Global Ltd. (RSG), operating through its Indian entity Jona Tech Systems Pvt. Ltd., is the exclusive authorized distributor of the Hyperfine Swoop\u00ae system across India. RSG is a vertically integrated advanced medical technology company headquartered in London with offices in New Delhi, Munich, Dubai, Singapore, Jakarta, and Sydney, focused on driving innovative technologies into high-growth markets and expanding patient access to world-class diagnostics.<\/p>\n
\n
<\/b>This press release includes \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the \u201cCompany\u201d) may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieves,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company\u2019s goals and commercial plans, the benefits of the Company\u2019s products and services, and the Company\u2019s future performance and its ability to implement its strategy, including its entrance into new markets. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company\u2019s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company\u2019s product development and commercialization activities, including the degree that the Swoop\u00ae<\/i> system is accepted and used by healthcare professionals; the inability to maintain the listing of the Company\u2019s Class A common stock on the Nasdaq Stock Market; the Company\u2019s inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to progress on product advancements and improvements; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company\u2019s products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company\u2019s products and services and reimbursement for medical procedures conducted using the Company\u2019s products and services; anticipated National Institutes of Health funding pressures; the effect of U.S. export controls and tariffs; the Company\u2019s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company\u2019s financial performance; and other risks and uncertainties indicated from time to time in the Company\u2019s filings with the Securities and Exchange Commission, including those under \u201cRisk Factors\u201d therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.<\/p>\n<\/p>\n
\n<\/b>
Devin Zell
\n
Hyperfine
\n
dzell@hyperfine.io
\n<\/a><\/p>\n
\n<\/b>
Webb Campbell
\n
Gilmartin Group LLC
\n
webb@gilmartinir.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260429706357\/en\/2375273\/3\/Hyperfine_Logomark_Full_Color_RGB_600px_tall.jpg\")
<\/td>\n<\/tr>\n